THE IMPACT OF PART 11 ON PROCESS ANALYTICAL TECHNOLOGY
This article was originally published in The Gold Sheet
Executive Summary
...is being considered as FDA and industry seek to remove obstacles to implementation of the new on-line control systems. The issue was a focal point at an agency advisory committee meeting in late October. Industry experts asserted that Part 11 electronic record controls should only apply to critical data, not raw data, to avoid being overwhelmed by the surge of information that will be generated by PAT systems. Overly strict computer validation expectations are seen as another PAT obstacle. Inspection citations regarding computer system validation and security, such as those recently levied against Eli Lilly, add to the industry concern.
You may also be interested in...
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
Biotech QbD Encounters Uncertainties Over Definitions and Regulatory Relief
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.